Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity of California, Berkeley

About this trial

The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) cluster randomized controlled trial in western Kenya will evaluate the impact of a multi-component chlorination intervention in health care facilities on maternal and neonatal health. Intervention facilities will receive a passive chlorination technology for water supply treatment and a reliable supply of sodium hypochlorite disinfectant. Both intervention and treatment facilities will receive infection prevention and control messaging. The goal of the study is to evaluate the impact of the intervention on bacterial contamination of water supply, on staff hands, and on high-touch surfaces in maternity wards, and the following outcomes among facility-born neonates and their mothers: (1) gut carriage of bacterial pathogens associated with sepsis one week post-birth, (2) gut carriage of antibiotic resistant bacteria one week post-birth, and (3) symptoms of possible serious bacterial infection one week following birth.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Public health care facility

25 live births or more per month

Infrastructure compatible with inline chlorination device

Pregnant adults/mature minors arriving at enrolled facilities to give birth and their neonates

Disqualifiers

Existing facility-level chlorination

Miscarriage (<28 weeks gestation)

Stillbirth (for neonatal analysis only)

Unable to give informed consent/do not consent

Trial design

Design model

Parallel

Treatments tested in this trial

  • chlorination for water disinfection and surface disinfection

    Device

    * Installation of inline chlorine doser(s) for automated water disinfection. * Provision of chlorine solution for water and surface disinfection (half of treatment facilities randomized to receive electrochlorinator, half receive bulk chlorine solution deliveries). * Provision of mop(s), bucket(s), and spray bottles for surface cleaning.

  • infection prevention and control messaging

    Behavioral

    Infection prevention and control guidance and messaging

Treatment groups

45,450 Participants
are divided into 2 treatment groups
Group A: ControlActive comparator 1 intervention
Group B: Multi-component chlorine interventionExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Possible serious bacterial infection in neonate

Cumulative incidence of one or more of the following severe infection symptoms of neonates based on WHO criteria for possible serious bacterial infection: 1. Not able to feed at all or not feeding well 2. Convulsions 3. Severe chest indrawing 4. Fever - High body temperature (38°C\* or above) 5. Low body temperature (less than 35.5°C\*) 6. Movement only when stimulated or no movement at all 7. Fast breathing (60 breaths per minute or more)

Time frame
From birth to 7 days post birth
2

Possible maternal sepsis

Any of the following listed with fever or hypothermia: 1. fast heartbeat 2. low blood pressure 3. respiratory distress 4. jaundice 5. decreased urination/dysuria 6. altered mental status

Time frame
From birth to 7 days post birth
3

Neonatal infection with at least one bacterial pathogen

Detection of any pre-specified bacterial pathogen detected by qPCR in infant rectal swabs (among swab subset of participants) Includes: ETEC, STEC, EPEC, EAEC, EIEC, EHEC O157:H7, Escherichia coli, Shigella spp, Shigella flexneri, Salmonella spp., Salmonella typhi, Campylobacter jejuni/coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus agalactiae (Group B strep), Pseudomonas aeruginosa, Acinetobacter baumannii, Clostridium difficile, Streptococcus pyogenes (Group A strep), Citrobacter freundii/braaki, Enterobacter cloacae

Time frame
7 days after birth
4

Neonatal rectal colonization with at least one bacterial pathogen by culture-based method measured 7 days after birth

Detection of any pre-specified bacterial pathogen detected by culture in neonate rectal swabs (among swab subset of participants) Includes: Salmonella spp., Shigella, Staphylococcus aureus,Streptococcus agalactiae (Group B strep)

Time frame
Approx 7 days after birth

Secondary outcomes

1

Maternal rectal colonization with at least one bacterial pathogen by culture-based method

Detection of any pre-specified bacterial pathogen detected by culture in maternal rectal swabs (among swab subset of participants) Includes: Salmonella spp., Shigella spp., Staphylococcus aureus

Time frame
7 days post birth
2

Any symptom or sign of infection in neonate

One or more of the following symptoms: Difficulty feeding, Hyperthermia/fever, Hypothermia, Tachypnea, Severe chest indrawing, Convulsions, Movement only when stimulated/no movement, Bulging fontanel, Labored breathing, Skin infection, Umbilical redness, Oozing ears, Diarrhea, Three or more loose or watery stools in a 24 hour period, Vomiting, Cyanosis, Cough, Runny nose or congestion, Tachycardia (\>160 bpm at rest)

Time frame
From birth until 7 days post birth
3

Any symptom or sign of infection in mother

One or more of the following symptoms: Hypothermia, Fever, Foul smelling vaginal discharge, Fits/convulsions, Tachycardia (\>100 bpm at rest), Low blood pressure, Diarrhea (self-defined), Difficulty breathing, Jaundice, Decreased urination or difficult or painful urination, Confusion or altered mental state, Mastitis, Chills, Body aches, Low appetite, Lower abdominal pain, Three or more loose or watery stools in a 24 hour period, Vomiting, Cough, Runny nose or congestion, Chest pain, Bloody stool, Skin infection

Time frame
From birth to 7 days post birth
4

Clinical diagnosis of sepsis in neonate

Abstracted diagnosis from medical charts OR self-reported diagnosis confirmed by clinician

Time frame
From birth to 7 days post birth

Other outcomes

1

Staff job satisfaction

Proportion of healthcare staff reporting satisfaction with job

Time frame
baseline and 4,8,12, 16, 20, and 24 months post-intervention
2

Symptoms or signs of diarrheal or respiratory infection among health facility staff

7-day prevalence of self-reported fever, diarrhea, cough, or difficulty breathing

Time frame
baseline and 4,8,12, 16, 20, and 24 months post- intervention

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, Berkeley

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator

Kenya Medical Research Institute

Collaborator

Walter Reed Army Institute of Research (WRAIR)

Collaborator